AIM - AIM Notice - 11/06/2026
RNS Number : 7897HAIM11 June 2026NOTICE
11/06/2026 - 08:00
The London Stock Exchange admits the following securities to trading on AIM:
Audioboom Group Plc
81,279
ORDINARY SHARES OF NO PAR VALUE FULLY PAID
(BJYJFG6)(JE00BJYJFG60)
Aura Energy Limited
1,197
ORDINARY SHARES OF NO PAR VALUE FULLY PAID (DI)
(BD1RHP4)(AU000000AEE7)
Avacta Group Plc
12,857,143
ORDINARY SHARES OF 10P EACH, FULLY PAID
(BYYW9G8)(GB00BYYW9G87)
Galantas Gold Corporation
1,114,212
COMMON SHARES OF NO PAR VALUE, FULLY PAID
(BM962Z1)(CA36315W3012)
HUTCHMED (China) Limited
Block Admission
43,616,756
ORDINARY SHARES OF USD0.10 EACH, FULLY PAID (DI)
(BJQ2P07)(KYG4672N1198)
If you have any queries or require further information, please contact Market Operations on 020 7797 4310.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDAMOBGGDLRUBDGLG
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation